Cellular & Molecular Immunology

Papers
(The TQCC of Cellular & Molecular Immunology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Necroptosis, pyroptosis and apoptosis: an intricate game of cell death986
NLRP3 inflammasome activation and cell death649
Tumor-infiltrating lymphocytes in the immunotherapy era491
An update on the regulatory mechanisms of NLRP3 inflammasome activation372
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity267
Neutrophils in chronic inflammatory diseases246
The blood–brain barrier in systemic infection and inflammation244
Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases224
Gut microbiome, liver immunology, and liver diseases216
Dendritic cell migration in inflammation and immunity210
Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors208
Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids201
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron180
Metabolism of tissue macrophages in homeostasis and pathology180
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells178
Manganese salts function as potent adjuvants157
SARS-CoV-2-specific T cells in infection and vaccination134
Activation or exhaustion of CD8+ T cells in patients with COVID-19131
SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy130
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors124
The cutting-edge progress of immune-checkpoint blockade in lung cancer121
Tumor-associated myeloid cells: diversity and therapeutic targeting120
Immunological mechanisms and therapeutic targets of fatty liver diseases118
Dendritic cells in cancer immunology118
Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients113
Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response111
Neutralizing antibodies for the prevention and treatment of COVID-1999
SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation98
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment93
Neutrophils in liver diseases: pathogenesis and therapeutic targets90
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection86
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor86
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies85
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods84
Immunopathobiology and therapeutic targets related to cytokines in liver diseases83
T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant82
Impact of intracellular innate immune receptors on immunometabolism82
Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm79
Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia78
Autoimmmune hepatitis76
Microglia as hackers of the matrix: sculpting synapses and the extracellular space75
Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis74
The aryl hydrocarbon receptor and the gut–brain axis73
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy72
Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice71
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy71
T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals69
The roles of microglia in viral encephalitis: from sensome to therapeutic targeting68
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy67
Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren’s syndrome by modulating the function of myeloid-derived suppressor cells66
Protein N-myristoylation: functions and mechanisms in control of innate immunity63
Protein synthesis, degradation, and energy metabolism in T cell immunity61
Diet, lipids, and antitumor immunity61
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy59
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation59
Biology and pathology of the uterine microenvironment and its natural killer cells56
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice55
The therapeutic implications of immunosuppressive tumor aerobic glycolysis54
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy53
Metabolic programming in dendritic cells tailors immune responses and homeostasis53
A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy51
SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-1948
Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects48
Microenvironmental influences on T cell immunity in cancer and inflammation47
Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection47
0.032439947128296